Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Pharmacol Ther. 2018 Oct 3;194:222–254. doi: 10.1016/j.pharmthera.2018.10.002

Table 11.

Anti-cancer drugs targeting muscarinic receptor subtypes in lung cancer

Name of drug Specificit

y		 Cell line Activity Model Reference

s
Pirenzepine M1R A549 Inhibition of

TGF-β1 and

carbachol-

induced EMT		 Cell culture 128, 359
Methoctramine M2R A549, PC-9 Inhibition of

EMT, invasion,

migration		 Cell culture

athymic

mice		 376, 377
Darifenacin M3R H520, H82 Inhibition of cell

growth		 Cell culture

athymic

mice		 7, 299,

301, 305
Darifenacin M3R H1299 Inhibition of cell

growth		 Cell culture 128
4-DAMP M3R H82, H1694,

SBC3		 Inhibition of

proliferation,

viability,

angiogenesis and

carbachol-

induced EMT		 Cell culture,

athymic

mice		 31, 301,

306, 359,

369
Tiotropium M3R H520 Inhibition of cell

growth		 Cell culture,

athymic

mice		 295, 296
R2BHJJ and

R2PHC		 M3R A549,

H1299,

H157, H460		 Inhibition of

viability, cell

cycle progression		 Cell culture 128
AFDX-116 M2R/M4

R		 H1299 Inhibition of

viability		 Cell

culture		 128
P-F-HHSiD M3R H82 Inhibition of

viability		 Cell

culture		 301
J-115311 M3R H82 Inhibition of

viability, cell

growth		 Cell

culture,

orthotopic

mouse

model		 7